Status: Recruiting

How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.

Participants needed: 8

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sumitomo Pharma America, Inc.Updated: Apr 8, 2026Locations: 2

Eligibility criteria

Male or female, of any race, ≥ 18 years of age. Female patients must be surgical... [+6]

Histologic diagnosis of acute promyelocytic leukemia. [+20]

Status: Recruiting

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.

Participants needed: 114

Trial details

Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Updated: Aug 11, 2025Locations: 3

Eligibility criteria

Subjects voluntarily participate in this study, sign the informed consent form,... [+13]

Patients with other malignant tumors that occurred within 3 years before the fir... [+29]